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1. Introduction
Candida albicans normally resides as a harmless yeast in the 
GI and urinary tracts, and to a lesser extent on the skin, of 
most humans. However, for patients with weakened immune 
systems (e.g., AIDS patients, transplant recipients, and prema-
ture infants) C. albicans is an opportunistic and often deadly 
pathogen that will invade host tissues, undergo a dimorphic 
shift, and then grow as a fungal mass in the kidney, heart, or 
brain. Candida albicans is the fourth leading cause of hospi-
tal-acquired infection in the United States and over 95% of 
AIDS patients will suffer from infections by C. albicans.[1] 
and [2] There is a pressing need for new treatments for fungal 
infections.
Candida albicans is a polymorphic fungus able to grow as 
yeasts, hyphae, and pseudohyphae, and a great many chemical 
and environmental factors influence the relative populations of 
these morphologies. In liquid culture, C. albicans develops as 
either yeasts or hyphae, depending in part on whether the cell 
densities are above or below 106 cells per ml.3 Our research 
revealed that the population dependence of C. albicans mor-
phology results from the continuous production and detection 
of the sesquiterpene farnesol (1, Table 1),[3] and [4] which acts 
to block the yeast to mycelium transition at concentrations as 
low as 1–2 μM.[5] and [6] In accordance with the precedent es-
tablished for homoserine lactones in Gram-negative bacteria,7 
the phenomenon was termed quorum sensing. Farnesol was 
the first quorum-sensing molecule (QSM) to be discovered in 
an eukaryotic system.[3] and [4] 
The dimorphic nature of C. albicans is essential for patho-
genicity.8 The discovery of a QSM able to direct growth in 
the yeast phase therefore suggested the possibility of a “sin-
gle morphology therapy” which would force this opportunis-
tic pathogen to remain in a monomorphic, nonpathogenic life-
style. However, three separate experiments have shown that 
farnesol actually increases fungal pathogenicity. First, cultures 
of C. albicans pretreated with subinhibitory doses of flucon-
azole, a protocol that increases the levels of secreted farnesol 
8- to 10-fold,9 were 4- to 5-fold more pathogenic to mice.10 
Second, mice which received farnesol either in their drinking 
water or via intraperitoneal injection showed ca. 4-fold higher 
lethality from candidiasis than mice receiving control IP in-
jections.11 Third, a knockout mutant of C. albicans lacking the 
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DPP3 gene encoding an isoprenoid pyrophosphatase for con-
version of farnesyl pyrophosphate to farnesol, and thus pro-
ducing only 15% as much farnesol as the wild-type, was 4- to 
5-fold less pathogenic. Reconstitution of DPP3 restored both 
farnesol production and pathogenicity.11 Taken together, these 
observations show that farnesol can act as a virulence factor 
for C. albicans. We have subsequently discovered a potential 
basis for this behavior, in that farnesol interferes with the nor-
mal progression of cytokine induction in mice infected with 
C. albicans.12
We are interested in the relationships between quorum 
sensing and virulence and, in particular, whether it is possi-
ble to decouple the two. Specifically, we were interested in the 
possibility of designing analogs that retain farnesol’s ability 
to block hyphal development but lack farnesol’s activity as a 
virulence factor. In order to explore this problem, we required 
potent QSMs structurally distinct from farnesol. We now re-
port the discovery of a series of highly potent synthetic quo-
rum-sensing molecules, as well as preliminary investigations 
of their activity in a mouse model of systemic candidiasis.
2. Results
When we initiated these studies, there were no synthetic mol-
ecules possessing a significant fraction of farnesol’s biologi-
cal activity as a quorum-sensing molecule. Previously, we had 
probed farnesol’s mode of action with over 40 natural and syn-
thetic farnesol analogs.6 Modified structural features included 
the head group, chain length, presence or absence of the 
three double bonds, substitution of a backbone carbon by S, 
O, N, and Se heteroatoms, presence or absence of a 3-methyl 
branch, and bulkiness of the hydrophobic tail. Although, more 
than half the compounds showed measurable quorum-sensing 
activity (inhibition of hyphal development), the best displayed 
only 7% of the activity of E,E-farnesol.6
2.1. Oxime leads for new QSMs
While developing a series of fluorescent farnesol ana-
logs,13 we discovered a pentaene oxime 2 with QSM activ-
ity (IC50 = 10 μM) superior to any previously investigated 
analog (Table 1; see the experimental section for a descrip-
tion of the QSM assay). Based on this discovery, we pre-
pared the oxime of farnesaldehyde (3) and found it was also 
a potent QSM (IC50 = 5 μM, Table 1). The corresponding O-
methyl ether, farnesaldehyde methoxyoxime 4, was inactive 
(IC50 > 100 μM), consistent with the results of earlier stud-
ies pointing to a requirement for an acidic head group.6 How-
ever, oxime 3 was found to exhibit significant toxicity (IP) 
in healthy mice and this class of molecules was not pursued 
further.
2.2. Tetrazole QSMs
The high quorum-sensing activity of oximes 2 and 3 led us 
to explore replacement of the primary alcohol of farne-
sol with other acidic functional groups (Fig. 1). Our earlier 
work had found farnesoic acid to be a weakly active QSM 
(IC50 = 36 μM).
6 5-Substituted-1H-tetrazoles are weak acids 
(pK ~ 5) often used as lipophilic isosteres for carboxylic ac-
ids,[14] and [15] and therefore we investigated several analogs in-
corporating a tetrazole in place of C1–C3 of farnesol. 
Analogs 5, 6, and 7 were synthesized via cycloaddition of 
the appropriate nitrile with Et3NHN3, generated in situ from 
NaN3 (Scheme 1).
16 
Analog 5, which incorporates a tetrazole in place of the 
C1–C3 region of farnesol, was a potent QSM with IC50 = 7 μM 
(Table 2). However, in agreement with conclusions from our 
earlier research,6 chain length was clearly important. Tetrazole 
6, although possessing only one fewer backbone carbon than 5, 
was considerably less active, while commercially available 5-
methyl-1-tetrazole (not shown) was inactive as a QSM at con-
centrations up to 3 mM. Nonyl tetrazole 7 and commercially 
Table 1. QSM activity of oximes 
a Inhibition of germ tube formation.
b Healthy mice observed over 14 d following injection (IP) with 1 ml of 20 
mM solution (0.5% Tween 80 v/v in sterile, nonpyrogenic saline).
c Not determined.
d Mice died within 4–5 days.
Figure 1. Design concept for analogs. 
Scheme 1. Synthesis of Tetrazoles. 
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available styrenyl tetrazole 8 were also highly active; how-
ever, 7 was only marginally soluble in water. The strong quo-
rum-sensing activity observed for analogs 5 and 8 implies a 
functional equivalency between styrene and 4,8-dimethyl-3,7-
nonadiene sidechains, suggesting that 3-methyl-5-phenyl-2,4-
pentadienol or similar structures might represent productive 
future targets as synthetic QSMs.17 Along these lines, it is in-
teresting to note a report indicating that dodecanol, an analog 
of the 12-carbon homoserine lactone secreted as a QSM by 
Pseudomonas aeruginosa, is a weak QSM for C. albicans.18 
2.3. Other heterocyclic QSMs
The potency of the tetrazoles as quorum-sensing molecules 
led us to investigate additional examples of five-membered 
heterocyclic analogs possessing the same approximate shape, 
crosssection, lipophilicity, and molecular length (Scheme 2). 
Our previous studies had found the replacement of a meth-
ylene with a sulfur atom (thioether) to be a well-tolerated 
structural modification,6 and we therefore mainly focused on 
sulfur-linked heterocycles, which are readily available via nu-
cleophilic displacement (Scheme 2).19 A similar approach has 
been employed for synthesis of a thiotriazole from farnesyl 
chloride.20 The substrates tested grafted a series of heterocy-
clic head groups onto a geranyl (3,7-dimethyl-2,6-octadienyl) 
tail: thio-1,2,3,4-tetrazole (9), thio-1,2,4-triazole (10), thio-
1,2,3-triazole (11), and thioimidazole (12). We also investi-
gated a carbon-linked 1,2,3-triazole (13) prepared through a 
dipolar cycloaddition (Eq. 1).21
(1)
Although thiotetrazole 9 and thioimidazole 12 were only 
minimally active (IC50 > 50 μM), triazoles 10, 11, and 13 
were potent QSMs (Table 3). It is notable that two of the ana-
logs (10 and 13) exhibit QSM activity equal to E,E-farnesol, 
with three other analogs (5, 7, and 11) displaying activities 
nearly as great. It is important to note that none of the com-
pounds listed in Table 1 and Table 2 had any inhibitory effects 
on the rate of cell growth, even at the highest concentrations 
tested (≥100 μm). 
2.4. Effect of heterocyclic QSMs on candidiasis
In selecting analogs for mouse assays, we eliminated the 
nonyl tetrazole 7 due to limited water solubility. Three of the 
most potent synthetic QSMs (5, 10, and 11) were tested next 
for their potential toxicity to mice following IP injection of 
1 ml of a 20 mM solution (ca. 4.4 mg of analog in 0.5% v/
v Tween 80 in sterile, nonpyrogenic saline). Attempts to use 
0.1% Triton X-100 in place of Tween 80 were precluded by 
toxicity. In an initial experiment with 3 mice per group, no 
toxicity was observed for at least 14 days following injection. 
In a follow-up experiment with 15 mice per group, also ob-
served for at least 14 days, injection of 11 caused a slight peri-
tonitis and mild hepatomegaly in some mice. Therefore, ana-
logs 5 and 10 were chosen for further testing with a standard 
mouse model of candidiasis,[10] and [11] employing tail vein in-
jection of C. albicans cells and IP injection of the analogs.
Forty-five mice were inoculated with 5 × 106 cells of C. al-
bicans A72 through tail vein injection; an additional 45 mice 
were inoculated with 2 × 106 cells. Each batch of mice was di-
vided into 3 groups of 15 mice each. The chosen doses pro-
vide ca. 50% mortality after 3 days with strain C. albicans 
A72;10 virtually identical results were obtained with each 
dose. Group 1 was given a control injection (IP, 1 ml of 0.5% 
Tween 80 in saline) while groups 2 and 3 were injected with
Table 2. Quorum sensing and toxicity of tetrazoles 
a,b See Table 1.
Table 3. Quorum sensing and toxicity in 9–13 
a,b See Table 1; c R = geranyl.
Scheme 2. Additional heterocyclic analogs. 
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analogs 5 and 10, respectively. Neither analog protected the 
mice from candidiasis (Fig. 2). In the case of the thiotriazole 
10, mouse lethality closely paralleled that observed for the 
control Tween 80 injections. In contrast, coadministration of 
tetrazole 5 enhanced the pathogenicity of C. albicans A72 ca. 
4- to 5-fold, almost exactly duplicating the effects of farne-
sol.[10] and [11] The effect is sufficiently pronounced that the en-
tire group of 15 mice treated with 5 died within 60 h of infec-
tion. It is noteworthy that 5 and 10 display opposing effects 
in vitro (QSM) and in vivo (pathogenicity). Thiotriazole 10 
is ca. 7-fold more potent than 5 as a QSM but, unlike the tet-
razole, it does not act as a farnesol-mimic in promoting viru-
lence. Thus, the two analogs uncouple the in vitro and in vivo 
effects of farnesol. 
3. Discussion
Farnesol is a biologically active, lipid-soluble molecule. We 
have shown that it blocks the yeast to mycelium transition in 
C. albicans,3 acts as a virulence factor in a mouse model of 
systemic candidiasis,[10] and [11] probably by interfering with 
the normal progression of cytokine expression in their immune 
response,12 and triggers apoptosis in the fungus Aspergillus 
nidulans.22 Others have shown that farnesol alters circadian 
rhythms in Neurospora crassa and targets HMG CoA reduc-
tase for proteolysis in both Saccharomyces cerevisiae and 
Chinese hamster ovary cells.[23], [24] and [25] Farnesol has also 
been shown to block calcium channels, stimulating cell dif-
ferentiation, and triggering apoptosis in other mammalian cell 
lines.26 Farnesol-induced apoptosis has also been reported in 
tobacco cells.27 In addition, farnesol has recently been found 
to be a potent and selective inhibitor of one class of mono-
amine oxidases (MAO-B).28 The family of heterocyclic farne-
sol analogs described above now provides a tool to discrimi-
nate between yeast-hyphal quorum sensing and pathogenicity. 
In particular, the availability of molecules such as tetrazole 5 
(a potent quorum-sensing molecule which enhances pathoge-
nicity) and 10 (a potent quorum-sensing molecule which does 
not enhance pathogenicity) may provide a potent tool in un-
derstanding how farnesol functions as a virulence factor in in-
teractions with cellular macrophages and CD4 T cells to alter 
adaptive immunity.12 The analogs also provide a means of es-
tablishing differences and similarities between farnesol’s ef-
fect on virulence and its ability to block both hyphal devel-
opment and biofilm formation.[3] and [29] Along these lines, it 
is interesting to note that an analog of triazole 10 bearing five 
additional carbons has been reported to be a potent activator 
of protein kinase C.20 Of course, the differences in the patho-
genicity of C. albicans observed in the presence of farnesol, 
5, and 10 could also be due to differing pharmacokinetics or 
their differing influence on mouse cytokine production.
It is also intriguing to consider the basis for the failure of 
farnesol, tetrazole 5, or thiotriazole 10 to exert any protective 
role on the course of systemic candidiasis. One possibility is 
that the conditions of the experiment were not well suited to 
test the potential of quorum-sensing molecules as fungistatic 
therapeutics. Mycelia, the invasive form of the fungi capable 
of penetrating host tissues to enter the bloodstream, are dis-
favored by the addition of exogenous farnesol or synthetic 
QSMs. However, the standard experimental protocol calls 
for injection of C. albicans directly into the bloodstream (tail 
vein), potentially minimizing the influence of any regimen 
that disfavors the mycelial morphology. Three other clinical 
models of candidiasis, oral,30 vaginal,31 and gastrointestinal,32 
may provide a more relevant test of the potential of a ‘single 
morphology’ therapy for control of fungal infections.
4. Conclusion
We have discovered a family of synthetic quorum-sensing 
molecules for C. albicans possessing in vitro potency com-
parable to E,E-farnesol, the natural signal. Investigations of 
several of the analogs in a mouse model reveals no protection 
against systemic candidiasis, but do demonstrate the ability to 
decouple quorum sensing and virulence, suggesting this fam-
ily of farnesol analogs may prove extremely useful in dissect-
ing the basis for farnesol’s many biological activities.
5. Experimental
5.1. General procedures
Tetrahydrofuran (THF) was distilled from sodium/benzo-
phenone. Other solvents were used as received. All reactions 
were performed under N2 in oven-dried or flame-dried glass-
ware. All new compounds were characterized by 1H, 13C, IR, 
and HRMS. NMR spectra were recorded at 400 MHz (1H) or 
100 MHz (13C) in CDCl3 unless otherwise noted. IR spec-
tra were collected on NaCl plates. Melting points are uncor-
rected. Mass spectra were acquired at the Nebraska Center for 
Mass Spectrometry (Lincoln, NE). TLC analyses were con-
ducted on Analtech 0.25 mm GHLF plates, with analytes vi-
Figure 2. Influence of 5 and 10 on systemic candidiasis. Mouse mortality in 
the presence and absence of tetrazole 5 and triazole 10 following inoculation 
with C. albicans A72 (5 × 106 cells) and IP injection of 1 ml of: • (saline); ▲ 
(20 mM thio-1,2,4-triazole 10 in 0.5% Tween 80); ■ (20 mM tetrazole 5 in 
0.5% Tween 80). 
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sualized by UV, by dipping in 1% KMnO4 (specific for al-
kenes), or by charring after exposure to an aqueous solution 
of ceric sulfate and ammonium molybdate (general indica-
tor). (E)-5-(2-phenylethyenyl)-1H-tetrazole (8) was purchased 
from Alfa Aesar (“listed as 5-styryl-1H-1,2,3,4-tetrazole”) and 
used without purification. Abbreviations: EA, ethyl acetate; 
hex; hexane; HOAc, acetic acid; NBA, 3-nitrobenzylalcohol.
5.2. Assay of quorum sensing
Assays for quorum sensing,3 toxicity to mice,[10] and [11] and 
mortality have been described;[10] and [11] a brief overview fol-
lows: undifferentiated cells are inoculated to a final density 
of 1–2 × 107 cells/ml into a solution of N-acetyl glucosamine 
(2.5 mM, buffered to pH 7) and incubated for 4 h while shak-
ing (200 rpm, 37 °C), after which the relative percentage of 
cells with germ tube formation (GTF) is determined. Values 
from triplicate readings are always within 10% of the mean 
value. The relative percentage of cells displaying GTF, 95–
98% for cells grown on unsupplemented media, is reduced 
considerably in the presence of farnesol or related QSMs.5
5.3. Preparation of Substrates
The preparation of oximes 2 (anti, 2E,4E,6E,8E)-3,7,11-tri-
methyldodeca-2,4,6,8,10-pentaenal oxime)13 and 3 (anti, 
2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienal oxime)33 has 
been described.
5.3.1. anti- and syn-(2E,6E)-3,7,11-Trimethyldodeca-2,6,10-
trienal,O-methyl oxime [anti-4 and syn-4]
Into a pyridine solution (5 ml) of methoxylamine hydro-
chloride (0.109 g, 1.3 mmol) was added (2E,6E)-3,7,11-tri-
methyldodeca-2,6,10-trienal (0.115 g, 0.52 mmol; available 
through oxidation of commercially available farnesol with 
MnO2 or chromic acid). After 4 h the reaction mixture was di-
luted with water (50 ml) and extracted with 30% Et2O/Hex 
(100 ml). The organic layer was dried over Na2SO4 and con-
centrated under reduced pressure to afford a mixture which 
was separated by flash chromatography (2% Et2O/Hex) to af-
ford a mixture of anti-4 (0.080 g, 62%) and syn-4 (0.045 g, 
38%).
anti-4. Rf = 0.3 (5% EA/Hex); 
1H δ 8.01 (d, 1H, J = 10.4), 
5.92 (d, 1H, J = 9.6), 5.09 (m, 2H), 3.86 (s, 3H), 2.15 (m, 4H), 
2.05 (m, 2h), 1.97 (m, 2H), 1.82 (d, 3H, J = 1.2), 1.68 (s, 3H), 
1.60 (s, 6H); 13C δ 147.7, 147.5, 135.8, 131.3, 124.2, 123.2, 
117.8, 61.5, 40.0, 39.6, 26.7, 26.0, 25.7, 17.7, 17.2, 16.0; IR 
2965, 2932, 2855, 1443, 1051; MS (HR FAB, 3-NBA) calcd 
for C16H28NO (MH
+): 250.2171; found 250.2160 (4.4 ppm).
syn-4. Rf = 0.2 (5% EA/Hex) 
1H δ 7.27 (d, 1H, J = 10), 
6.41 (dd, 1H, J = 10, 1.2), 5.09 (m, 2H), 3.90 (s, 3H), 2.17 (m, 
4H), 2.06 (m, 2H), 1.98 (m, 2H), 1.87 (d, 3H, J = 1.2), 1.69 
(d, 3H, J = 0.8), 1.61 (s, 6H); 13C δ 149.8, 144.8, 135.9, 131.4, 
124.2, 123.2, 113.3, 61.8, 40.2, 39.7, 26.7, 26.1, 25.7, 17.7, 
17.1, 16.0; IR 2964, 2932, 2855, 1639, 1441, 1056; MS (HR 
FAB, 3-NBA) calcd for C16H28NO (MH
+): 250.2171; found 
250.2166 (1.8 ppm).
5.3.2. (E)-5,9-Dimethyldeca-4,8-dienenitrile
This compound was prepared by a variant of a known 
procedure.34 Into a −78 °C solution of acetonitrile (0.52 ml, 
10 mmol) in dry THF (10 ml) was added dropwise n-BuLi 
(5 mmol, 2.0 ml, nominally 2.5 M in hexane), followed by 
geranyl chloride (0.37 ml, 2.0 mmol). The reaction was al-
lowed to warm to rt, and, after 30 min, quenched with water. 
The mixture was extracted with 10% EA/hex (150 ml) and the 
organic layer was dried over Na2SO4. The crude residue ob-
tained upon concentration was purified by flash chromatogra-
phy (5% EA/Hex) to afford 0.28 g (79%) of the nitrile as a 
colorless oil: Rf = 0.2 (5% EA/Hex).
5.3.3. (E)-5-(4,8-Dimethylnona-3,7-dienyl)-1H-tetrazole (5)
Into a suspension of NaN3 (0.455 g, 7.00 mmol) in tolu-
ene (5 ml) was added Et3NHCl (Fluka, 1.10 g, 8.00 mmol) fol-
lowed by a solution of (E)-5,9-dimethyldeca-4,8-dienenitrile 
(see above, 2.00 mmol, 0.354 g) in 2 ml of toluene. The reac-
tion mixture was held at reflux for 24 h and then allowed to cool 
to rt. The mixture was acidified to pH  1 with 10% aq HCl 
and extracted with 20% EA/Hex (3× 100 ml). The combined 
organic layers were concentrated under reduced pressure and 
the residue purified by flash chromatography (Hex/EA/AcOH 
10:2:1) to furnish 0.41 g (93%) of tetrazole 5 as a colorless oil: 
Rf = 0.3 (5:1:1, Hex/AcOH/EA); 
1H δ 13.55 (br s, 1H), 5.18 
(t, 1H, J = 6.8), 5.04 (t, 1H, J = 6.5), 3.14 (t, 2H, J = 7.6), 2.56 
(q, 2H, J = 7.2), 2.03 (m, 2H), 1.97 (m, 2H), 1.66 (s, 3H), 1.66 
(s, 3H), 1.58 (s, 3H), 1.52 (s, 3H); 13C δ 156.5, 138.4, 132.0, 
124.0, 121.3, 39.5, 26.4, 26.1, 25.6, 23.7, 17.7, 15.9; IR 2917, 
2625, 1558, 1441, 1376, 1253; HR-FABMS (3-NBA) calcd for 
C12H21N4 (MH
+): 221.1766; found: 221.1771 (2.1 ppm).
5.3.4. (E)-4,8-Dimethylnona-3,7-dienenitrile35
Into a solution of NaCN (0.196 g, 4.00 mmol) in ethanol 
(10 ml) was added geranyl chloride (0.37 ml, 2.0 mmol). The 
reaction mixture was stirred for 2 h, diluted with water, and 
with 5% EA/Hex (twice). The separated organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (5% EA/Hex) to furnish 
0.313 g (96%) of the known nitrile: Rf = 0.3 (5% EA/Hex).
5.3.5. (E)-5-(3,7-Dimethylocta-2,6-dienyl)-1H-tetrazole (6)
This compound was prepared from (E)-5-(3,7-dimethyl-
octa-2,6-dienenitrile (0.31 g, 1.9 mmol) by a similar approach 
as for 5. The product (0.37 g, 95%) was a colorless crystal 
(mp = 52–54 °C, uncorrected) used without further purifica-
tion: Rf = 0.3 (5:1:1, Hex/AcOH/EA); 
1H δ 12.8 (br s, 1H), 5.45 
(dt, 1H, J = 7.2, 1.2), 5.05 (m, 1H), 3.82 (d, 2H, J = 7.6), 2.05 
(m, 4H), 1.69 (s, 3H), 1.68 (s, 3H), 1.57(s, 3H); 13C δ 156.0, 
141.5, 132.2, 123.9, 115.7, 39.3, 26.2, 25.6, 22.5, 17.6, 16.2; IR 
3417, 2971, 2916, 2732, 2253; HR-FABMS (3-NBA) calcd for 
C11H19N4 (MH
+): 207.1610; found: 207.1612 (1.3 ppm).
5.3.6. 5-Nonyl-1H-tetrazole (7)
This compound was prepared from decanonitrile (0.38 ml, 
2.0 mmol) by a similar method as employed for synthesis of 
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5 and 6. The crude material (0.359 g, 91%) displayed spectra 
identical to literature reports36 and was used without further 
purification: Rf = 0.2 (5:1:1, Hex/AcOH/EA).
5.3.7. (E)-5-(3,7-Dimethylocta-2,6-dienylthio)-1H-tetrazole 
(9)
Into a solution of 5-mercapto-1H-tetrazole (0.20 g, 
2.0 mmol) in ethyl alcohol (10 ml) were added K2CO3 (0.55 g, 
4.0 mmol) and geranyl chloride (0.19 ml, 1.0 mmol). After 
12 h, the reaction mixture was acidified to pH 7 and extracted 
with 50% EA/Hex (3× 50 ml). The combined organic extracts 
were dried with Na2SO4. The residue obtained upon concen-
tration in vacuo was purified by flash chromatography (5:1:1 
Hex/AcOH/EA) to furnish 0.213 g (89%) of mercaptotetra-
zole 9 as a colorless oil: Rf = 0.2 (5:1:1, Hex/AcOH/EA); 
1H 
δ 13.0 (br s, 1H), 5.37 (t, 1H, J = 7.6), 5.03 (t, 1H, J = 6.4), 
3.97 (d, 2H, J = 8), 2.03 (m, 4H), 1.68 (s, 3H), 1.66 (s, 3H), 
1.56 (s, 3H); 13C δ 155.1, 143.4, 132.1, 123.5, 116.8, 39.4, 
31.4, 26.2, 26.6, 17.7, 16.2; IR 3055, 2917, 2727, 2560, 1504, 
1447, 1038; HR-FABMS (3-NBA) calcd for C11H19N4 (MH
+): 
239.1330; found 239.1336 (2.2 ppm).
5.3.8. (E)-3-(3,7-Dimethylocta-2,6-dienylthio)-1H-1,2,4-tri-
azole (10)
Into a solution of 1H-1,2,4-triazole-3-thiol (0.152 g, 
1.50 mmol) in ethyl alcohol (10 ml) were added K2CO3 
(0.276 g, 2.00 mmol) and geranyl chloride (0.19 ml, 
1.0 mmol). After 12 h, the reaction mixture was worked up as 
for 9 and the residue purified by flash chromatography (40% 
EA/Hex) to furnish 0.235 g (99%) of thiotriazole 10: Rf = 0.3 
(50% EA/Hex); 1H δ 13.70 (br s, 1H), 8.18 (s, 1H), 5.33 (dt, 
1H, J = 1.2, 2), 5.02 (m, 1H), 3.80 (d, 2H, J = 8), 2.00 (m, 4H), 
1.64 (s, 3H), 1.56 (s, 3H); 13C δ 156.4, 147.7, 141.5, 131.8, 
131.8, 123.6, 118.1, 39.4, 31.2, 26.2, 25.6, 17.6, 16.0; IR 3111, 
2924, 1449, 1276, 910, 734; MS (HR-FABMS, 3-NBA) calcd 
for C12H20N3S, (MH
+): 238.1378; found: 238.1383 (2.3 ppm).
5.3.9. (E)-4-(3,7-Dimethylocta-2,6-dienylthio)-1H-1,2,3-tri-
azole (11)
Into a 0 °C solution of the sodium salt of 4-mercapto-1H-
1,2,3-triazole (0.262 g, 2.2 mmol) in ethanol (10 ml) was 
added geranyl chloride (0.19 ml, 1.0 mmol). The reaction mix-
ture was stirred for 2 h and then allowed to warm to RT over 
the course of 1 h. The reaction mixture was diluted with wa-
ter and the mixture extracted with 20% EA/Hex (3× 50 ml). 
The combined organic extracts were dried with Na2SO4 and 
concentrated, with the residue purified by flash chromatogra-
phy (20% EA/Hex) to furnish 0.218 g (92%) of thiotriazole 
11. Rf = 0.2 (20% EA/Hex); 
1H δ 14.23 (br s, 1H), 7.72 (s, 
1H), 5.28 (d of t, 1H, J = 1.2, 8), 5.02 (m, 1H), 3.54 (d, 2H, 
J = 7.6), 1.97 (m, 4H), 1.64 (d, 3H, J = 0.8), 1.55 (s, 3H), 1.47 
(s, 3H); 13C δ 140.7, 139.3, 133.5, 131.6, 123.7, 118.8, 39.3, 
33.0, 26.2, 25.5, 17.6, 15.7; IR 3130, 2916, 1661, 1448, 1228, 
1109, 839; HR-FABMS (3-NBA) calcd for C12H20N3S, MH
+: 
238.1378; found: 238.1369 (3.8 ppm).
5.3.10. (E)-2-(3,7-Dimethylocta-2,6-dienylthio)-1H-imidaz-
ole (12)
This compound was prepared from 2-mercaptoimidazole 
(0.12 g, 1.2 mmol) and geranyl chloride (0.19 ml, 1.0 mmol) 
in 96% yield (0.227 g) by a similar procedure as for 9. The 
crude product was pure by NMR and was utilized without fur-
ther purification: Rf = 0.4 (50% EA/Hex); 
1H δ 12.06 (br s, 
1H), 7.17 (s, 1H), 5.29 (dt, 1H, J = 1.2, 7.6), 5.03 (m, 1H), 
3.62 (d, 2H, J = 8), 2.05–1.92 (m, 4H), 1.65 (s, 3H), 1.56 (s, 
3H), 1.46 (s, 3H); 13C δ 140.5, 139.6, 131.6, 123.9, 123.8, 
119.0, 39.4, 33.4, 26.2, 25.6, 17.6, 15.6; IR 3094, 2916, 2637, 
1447, 1328, 1098; HR-FABMS (3-NBA) calcd for C13H20N2S 
(MH+): 237.1313; found 237.1310 (1.1 ppm).
5.3.11. (E)-4-(4,8-Dimethylnona-3,7-dienyl)-1H-1,2,3-tri-
azole (13)
Into a solution of (E)-6,10-dimethylundeca-5,9-dien-1-
yne37 (0.176 g, 1.00 mmol) in 9:1 DMF/MeOH (10 ml) was 
added TMSN3 (1.3 ml, 10 mmol) followed by CuI (0.1 g, 
0.5 mmol).21 The mixture was held at 100 °C for 12 h and 
then allowed to cool to rt. The reaction mixture was diluted 
with water and then extracted with 20% EA/Hex (3× 70 ml). 
The combined organic layers were dried with Na2SO4 and 
concentrated. The residue was purified by flash chromatogra-
phy (20% EA/Hex) to furnish 0.168 g (77%) of triazole 13: 
Rf = 0.2 (20% EA/Hex); 
1H (CD3OD) δ 7.53 (s, 1H), 5.15 (dt, 
1H, J = 1.2, 7.2), 5.05 (m, 1H), 2.76 (t, 2H, J = 7.6), 2.35 (q, 
2H, J = 7.2), 2.04 (m, 2H), 1.98 (m, 2H), 1.65 (s, 3H), 1.57 
(s, 3H), 1.54 (s, 3H); 13C (CD3OD, 100 MHz) δ 144.2, 137.7, 
132.3, 128.7, 125.4, 124.2, 40.9, 28.8, 27.8, 26.1, 24.2, 17.9, 
16.3; IR 3140, 2919, 2856, 1448, 1377, 1108, 983, 838; HR-
FABMS (3-NBA) calcd for C13H21N3 (MH
+): 220.1814; 
found: 220.1811 (1.1 ppm). 
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